Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL2308329 | 0.92 | ALDH1A1 (0.44) | ALDH1A1ADRA2BPTGS1TDP1CYP1A2 | |
| SCHEMBL202963 | 0.80 | ALDH1A1 (0.54) | ALDH1A1ADRA2BPTGS1TDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL1234308 | 0.78 | ALDH1A1 (0.52) | ALDH1A1ADRA2BPTGS1TDP1CYP1A2 | |
| SCHEMBL410485 | 0.73 | GAA (0.54) | ALDH1A1TDP1KDM4EMAPTAPP | |
| SCHEMBL8846148 | 0.72 | — | — | |
| SCHEMBL14925378 | 0.71 | MEN1 (0.43) | ALDH1A1TDP1MAPTSMN1; SMN2LMNA | |
| SCHEMBL1638392 | 0.71 | CA1 (0.62) | ALDH1A1ADRA2BPTGS1TDP1CYP1A2 | |
| SCHEMBL9132 | 0.71 | KDM4E (0.46) | ALDH1A1TDP1CYP1A2KDM4EALOX15 | |
| SCHEMBL10035451 | 0.71 | L3MBTL1 (0.42) | ALDH1A1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17563713 | 0.71 | FABP7 (0.35) | MAPTAPPLMNAGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12379383-B2 | Proteoform specific process validation | Novilytic, LLC (US) | 2025-08-05 | — | — | US | claimed |
| EP-4421168-A2 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2024-08-28 | — | — | EP | claimed |
| EP-4269578-B1 | SOLUBLE HYALURONIDASE COMPOSITION | HALOZYME INC (US) | 2024-06-05 | — | — | EP | claimed |
| EP-4269578-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2023-11-01 | — | — | EP | claimed |
| EP-4204158-A1 | PROTEOFORM SPECIFIC PROCESS VALIDATION | Novilytic, LLC (US) | 2023-07-05 | — | — | EP | claimed |
| US-20220137063-A1 | Proteoform Specific Process Validation | TENAX BIOANALYTICS, LLC | 2022-05-05 | — | — | US | claimed |
| WO-2022060947-A1 | PROTEOFORM SPECIFIC PROCESS VALIDATION | Novilytic, LLC (US) | 2022-03-24 | — | — | WO | claimed |
| EP-2268805-B1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME INC (US) | 2015-05-06 | — | — | EP | claimed |
| US-8557304-B2 | Method of obtaining secondary plant constituents | SARTORIUS STEDIM BIOTECH GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| US-8187855-B2 | Large-scale production of soluble hyaluronidase | HALOZYME, INC. (US) | 2012-05-29 | — | — | US | claimed |
| US-20120077994-A1 | METHOD OF OBTAINING SECONDARY PLANT CONSTITUENTS | SARTORIUS STEDIM BIOTECH GMBH (DE) | 2012-03-29 | — | — | US | claimed |
| US-20110053247-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME, INC. | 2011-03-03 | — | — | US | claimed |
| EP-2268805-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | Halozyme, Inc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009111066-A1 | LARGE-SCALE PRODUCTION OF SOLUBLE HYALURONIDASE | HALOZYME, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20070141678-A1 | Processes for purifying oligosaccharides | THE PROCTER & GAMBLE COMPANY | 2007-06-21 | — | — | US | claimed |
| EP-4746986-A1 | RADIAL FLOW SEPARATION DEVICE | Astrea UK Services Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12600959-B2 | PH20 polypeptide variants, formulations and uses thereof | HALOZYME, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-0487621-A4 | IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS | — | 1992-06-24 | — | — | EP | disclosed |
| EP-0487621-A1 | IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS. | UNIV NORTHWESTERN (US) | 1992-06-03 | — | — | EP | disclosed |
| WO-1991002978-A1 | IMMUNOASSAY OF GLYCOSYLATED PROTEINS EMPLOYING ANTIBODY DIRECTED TO REDUCTIVELY GLYCOSYLATED N-TERMINAL AMINO ACIDS | NORTHWESTERN UNIVERSITY (US) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600959-B2 | PH20 polypeptide variants, formulations and uses thereof | PREP, HM13, MMP20 | ALDH1A1 1859/4885ADRA2B 4073/4885PTGS1 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.